Download PDF

1. Company Snapshot

1.a. Company Description

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States.The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.


It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations.The company was incorporated in 2016 and is headquartered in Montreal, Canada.

Show Full description

1.b. Last Insights on RPTX

Repare Therapeutics' recent performance was driven by its Q3 earnings report, which showed break-even quarterly earnings per share, surpassing the Zacks Consensus Estimate of a loss of $0.35. The company's acquisition by XenoTherapeutics, Inc. for $1.82 per share, plus contingent value rights, also contributed to its performance. Additionally, the company's presentation of initial data from its Phase 1 LIONS clinical trial at the 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics showcased its progress in precision oncology.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—RPTX, CNBN, KMB, and KVUE

Dec -04

Source: globenewswire.com

Card image cap

Halper Sadeh LLC Encourages RPTX, THS, RMBI Shareholders to Contact the Firm to Discuss Their Rights

Nov -27

Source: globenewswire.com

Card image cap

Repare Therapeutics Inc. (NASDAQ:RPTX) Receives $3.50 Average PT from Brokerages

Nov -25

Source: defenseworld.net

Card image cap

Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.

Nov -20

Source: businesswire.com

Card image cap

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Repare Therapeutics Inc. (NASDAQ: RPTX)

Nov -17

Source: globenewswire.com

Card image cap

Repare Therapeutics Agrees To Acquisition As Board Cites Best Path For Stakeholder Value

Nov -17

Source: benzinga.com

Card image cap

RPTX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Repare Therapeutics Inc. is Fair to Shareholders

Nov -15

Source: businesswire.com

Card image cap

Shareholder Alert: The Ademi Firm investigates whether Repare Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Nov -15

Source: prnewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.00%)

6. Segments

Precision Oncology Drugs

Expected Growth: 10.0%

Repare Therapeutics Inc.'s Precision Oncology Drugs segment is driven by increasing demand for targeted therapies, advancements in genetic sequencing, and a growing understanding of cancer biology. The company's proprietary SNIPRx platform enables identification of novel targets, while strategic partnerships and collaborations accelerate drug development, contributing to the 10.0% growth rate.

7. Detailed Products

CAMI

CAMI (Cambridge Membrane Integrity) is a novel, first-in-class, oral small molecule that targets the DNA repair pathway to selectively kill cancer cells.

RP-6306

RP-6306 is a potent and selective inhibitor of the protein kinase ATR, which plays a critical role in the DNA damage response pathway.

RP-7065

RP-7065 is a novel, oral, small molecule inhibitor of the protein kinase CHK1, which is involved in the DNA damage response pathway.

8. Repare Therapeutics Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Repare Therapeutics Inc. is medium due to the presence of alternative treatments and therapies for cancer and genetic disorders.

Bargaining Power Of Customers

The bargaining power of customers for Repare Therapeutics Inc. is low due to the lack of negotiating power of individual patients and the high demand for innovative cancer treatments.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Repare Therapeutics Inc. is medium due to the presence of multiple suppliers for raw materials and equipment, but the high cost of switching suppliers.

Threat Of New Entrants

The threat of new entrants for Repare Therapeutics Inc. is high due to the growing interest in gene editing and cancer treatment, and the potential for new companies to enter the market.

Intensity Of Rivalry

The intensity of rivalry for Repare Therapeutics Inc. is high due to the presence of established companies and the high competition for market share in the gene editing and cancer treatment market.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 1.58%
Debt Cost 3.95%
Equity Weight 98.42%
Equity Cost 7.41%
WACC 7.36%
Leverage 1.61%

11. Quality Control: Repare Therapeutics Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Seer

A-Score: 4.5/10

Value: 8.0

Growth: 4.2

Quality: 4.6

Yield: 0.0

Momentum: 6.5

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
AbCellera Biologics

A-Score: 4.0/10

Value: 7.0

Growth: 1.1

Quality: 4.1

Yield: 0.0

Momentum: 10.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
2seventy bio

A-Score: 3.7/10

Value: 7.6

Growth: 4.4

Quality: 4.4

Yield: 0.0

Momentum: 5.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Curis

A-Score: 3.6/10

Value: 9.2

Growth: 3.9

Quality: 6.0

Yield: 0.0

Momentum: 1.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Repare Therapeutics

A-Score: 3.4/10

Value: 8.8

Growth: 4.8

Quality: 4.3

Yield: 0.0

Momentum: 0.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Vir Biotechnology

A-Score: 3.3/10

Value: 7.6

Growth: 3.6

Quality: 5.0

Yield: 0.0

Momentum: 2.0

Volatility: 1.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

2.21$

Current Price

2.21$

Potential

-0.00%

Expected Cash-Flows